- Quarterly Report (10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2010

¨	Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

COMMISSION FILE NO: 001-32569

AMERICAN ORIENTAL BIOENGINEERING, INC.

(Exact name of registrant as specified in its charter)

NEVADA	84-0605867
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1 Liangshuihe First Ave, Beijing E-Town Economic and Technology Development Area, E-Town,

Beijing, 100176, People’s Republic of China

(Address of principal executive offices) (Zip Code)

86-10-5982-2039

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	¨	Accelerated filer	x
Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares outstanding of each class the issuer’s common stock as of the latest practicable date is stated below


Title of each class of common stock		Outstanding as of August 5, 2010
Common Stock, $0.001 par value		78,580,138

TABLE OF CONTENTS


PART I – FINANCIAL INFORMATION	3

ITEM 1 – Financial Statements	3

Unaudited condensed consolidated balance sheet as of June 30, 2010 and condensed consolidated balance sheet as of December 31, 2009	3

Unaudited condensed consolidated statements of income and comprehensive income for the three and six months ended June 30, 2010 and 2009	5

Unaudited condensed statements of cash flow for the six months ended June 30, 2010 and 2009	6

Notes to unaudited condensed consolidated financial statements - June 30, 2010	7

ITEM 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations	23

ITEM 3 – Quantitative and Qualitative Disclosures About Market Risk	34

ITEM 4 – Controls and Procedures	34

PART II – OTHER INFORMATION	35

ITEM 1 – Legal Proceedings	35

ITEM 1A – Risk Factors	35

ITEM 2 – Unregistered Sales of Equity Securities and Use of Proceeds	35

ITEM 3 – Defaults upon Senior Securities	35

ITEM 4 – Other Information	35

ITEM 5 – Exhibits	35

Signatures

PART I – FINANCIAL INFORMATION

ITEM 1 – FINANCIAL STATEMENTS

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

ASSETS

	JUNE 30, 2010		DECEMBER 31, 2009

CURRENT ASSETS
Cash and cash equivalents	$	96,433,832	$	91,126,486
Restricted cash		1,103,535		3,298,379
Accounts and notes receivable, net		66,767,659		57,504,454
Inventories, net		19,016,578		10,015,711
Advances to suppliers and prepaid expenses		5,937,021		13,901,180
Deferred tax assets		550,535		824,451
Other current assets		1,347,639		1,246,647
Total Current Assets		191,156,799		177,917,308

LONG-TERM ASSETS
Property, plant and equipment, net		95,445,470		95,468,265
Land use rights, net		152,594,995		153,604,196
Other long term assets		7,967,784		7,909,086
Construction in progress		29,324,123		28,975,386
Other intangible assets, net		16,329,103		18,695,554
Goodwill		33,164,121		33,164,121
Investments in and advances to equity investments		57,441,048		57,325,887
Deferred tax assets		143,781		134,268
Unamortized financing cost		2,823,549		3,287,694
Total Long-Term Assets		395,233,974		398,564,457
TOTAL ASSETS	$	586,390,773	$	576,481,765

See accompanying notes to the condensed consolidated financial statements

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

LIABILITIES AND EQUITY

	JUNE 30, 2010			DECEMBER 31, 2009

CURRENT LIABILITIES
Accounts payable	$	11,477,039		$	7,497,143
Notes payable		1,103,535			3,392,575
Other payables and accrued expenses		16,935,522			22,320,757
Taxes payable		605,024			947,338
Short-term bank loans		8,959,257			10,384,368
Current portion of long-term bank loans		60,629			60,108
Other liabilities		4,842,631			2,199,280
Deferred tax liabilities		173,496			172,473
Total Current Liabilities		44,157,133			46,974,042

LONG-TERM LIABILITIES
Long-term bank loans, net of current portion		710,598			743,957
Deferred tax liabilities		15,652,960			15,961,465
Unrecognized tax benefits		3,871,701			2,746,561
Convertible notes		115,000,000			115,000,000
Total Long-Term Liabilities		135,235,259			134,451,983
TOTAL LIABILITIES		179,392,392			181,426,025

COMMITMENTS AND CONTINGENCIES

EQUITY
SHAREHOLDERS’ EQUITY
Preferred stock, $0.001 par value; 2,000,000 shares authorized; 1,000,000 shares issued and outstanding at June 30, 2010 and December 31, 2009, respectively		1,000			1,000
Common stock, $0.001 par value; 150,000,000 shares authorized; 78,580,138 and 78,321,439 shares issued and outstanding at June 30, 2010 and December 31, 2009, respectively		78,580			78,321
Common stock to be issued		181,500			388,000
Prepaid forward repurchase contract		(29,998,616	)		(29,998,616	)
Additional paid-in capital		201,806,789			199,829,921
Retained earnings (the restricted portion of retained earnings is $23,757,901 at both June 30, 2010 and December 31, 2009)		199,421,141			191,173,754
Accumulated other comprehensive income		34,986,727			33,050,224
Total Shareholders’ Equity		406,477,121			394,522,604
Non-controlling Interest		521,260			533,136
TOTAL EQUITY		406,998,381			395,055,740
TOTAL LIABILITIES AND EQUITY	$	586,390,773		$	576,481,765

See accompanying notes to the condensed consolidated financial statements

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(UNAUDITED)

	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2010			2009			2010			2009

Revenues	$	77,296,212		$	71,222,037		$	131,045,980		$	117,299,227
Cost of sales		37,455,860			29,594,923			62,968,907			47,255,261
GROSS PROFIT		39,840,352			41,627,114			68,077,073			70,043,966

Selling and marketing expenses		11,505,462			9,396,129			17,481,688			14,607,631
Advertising costs		9,217,247			7,779,936			15,965,717			13,347,293
Research and development costs		3,250,882			809,584			6,029,691			1,559,382
General and administrative expenses		5,158,104			4,026,425			9,924,590			8,417,126
Depreciation and amortization		1,622,989			1,623,556			3,219,947			3,256,142
Total operating expenses		30,754,684			23,635,630			52,621,633			41,187,574

INCOME FROM OPERATIONS		9,085,668			17,991,484			15,455,440			28,856,392

Equity in earnings (loss) from unconsolidated entities		(170,799	)		(173,258	)		(53,326	)		264,536
Interest expense, net		1,371,246			1,620,069			2,937,031			3,199,338
Other expenses, net		30,039			16,329			17,792			114,938
INCOME BEFORE INCOME TAX		7,513,584			16,181,828			12,447,291			25,806,652
Income tax		2,395,850			3,735,558			4,211,780			6,205,322
NET INCOME		5,117,734			12,446,270			8,235,511			19,601,330
Net loss attributable to non-controlling interest		6,476			123,068			11,876			119,517
NET INCOME ATTRIBUTABLE TO CONTROLLING INTEREST		5,124,210			12,569,338			8,247,387			19,720,847

OTHER COMPREHENSIVE INCOME		1,843,654			21,945			1,936,503			513,282

COMPREHENSIVE INCOME	$	6,967,864		$	12,591,283		$	10,183,890		$	20,234,129

EARNINGS PER COMMON SHARE
Basic	$	0.07		$	0.17		$	0.11		$	0.27
Diluted	$	0.07		$	0.16		$	0.11		$	0.26

WEIGHTED AVERAGE SHARES OUTSTANDING
Basic		74,743,986			74,582,920			74,680,327			74,560,809
Diluted		75,857,073			88,815,593			75,502,489			86,939,711

See accompanying notes to the condensed consolidated financial statements

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	SIX MONTHS ENDED JUNE 30
	2010			2009

CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	8,235,511	$	19,601,330
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		6,482,226		6,445,556
Amortization of deferred issuance cost		464,145		464,145
Loss on disposal of property, plant and equipment		370		4,745
Amortization of deferred consulting expenses		30,675		80,000
Provision for doubtful accounts and slow moving inventories		79,494		332,207
Deferred taxes		(43,079)		125,336
Amortization of stock-based compensation expense		1,280,829		1,127,500
Equity in (earnings)/loss from unconsolidated entities		53,326		(264,536	)
Independent director stock compensation		181,500		194,000
Changes in operating assets and liabilities, net of effects of acquisitions:
(Increase) decrease in:
Accounts and notes receivable		(9,346,105)		5,934,188
Inventories		(8,997,546)		(3,841,052)
Advances to suppliers and prepaid expenses		7,995,584		458,285
Other current assets		(121,192)		(192,184)
Increase (decrease) in:
Accounts payable		3,849,965		260,564
Other payables and accrued expenses		(5,831,985)		(5,514,977)
Taxes payable		(342,314)		204,590
Other liabilities		2,643,351		257,855
Unrecognized tax benefits		1,125,140		774,190
Net cash provided by operating activities		7,739,895		26,451,742

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment		(337,692)		(149,837	)
Purchases of construction in progress		(1,027,429)		(535,881)
Purchase of land use right		-		(757,187)
Refundable deposit		-		6,396,996
Deposit for long-term assets		(33,898)		(361,375)
Advances to equity investments		(11,221)		(172,812	)
Proceeds from disposal of property, plant and equipment		-		620
Net cash (used in) provided by investing activities		(1,410,240)		4,420,524

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from bank loans		4,543,075		9,181,237
Repayment of bank loans		(6,142,267)		(10,209,500	)
Net cash used in financing activities		(1,599,192)		(1,028,263)
Effect of exchange rate changes on cash and cash equivalents		576,883		206,056
NET INCREASE IN CASH AND CASH EQUIVALENTS		5,307,346		30,050,059
Cash and cash equivalents, beginning of period		91,126,486		68,060,769
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	96,433,832	$	98,110,828

See accompanying notes to the condensed consolidated financial statements

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

NOTE 1 - BASIS OF PRESENTATION

The unaudited condensed consolidated financial statements of American Oriental Bioengineering, Inc. and subsidiaries (the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, the information included in these interim financial statements reflects all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for the fair presentation of the consolidated financial position and the consolidated results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full year. The condensed consolidated balance sheet as of December 31, 2009 has been derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K. These interim financial statements should be read in conjunction with that report.

Basis of Consolidation

The unaudited condensed consolidated financial statements include the financial statements of American Oriental Bioengineering, Inc. and its subsidiaries. All significant inter-company balances and transactions between the Company and its subsidiaries are eliminated upon consolidation. Results of acquired subsidiaries are consolidated from the date on which control is transferred to the Company and are no longer consolidated from the date that control ceases.

Investments

The Company applies Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 323 “Investments - Equity Method and Joint Ventures” in accounting for its equity investments. Under FASB ASC 323 equity method is used for investments in entities in which the Company has the ability to exercise significant influence but does not own a majority equity interest or otherwise control. The cost method is used for investments over which the Company does not have the ability to exercise significant influence or control.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates reflected in the consolidated financial statements include, but are not limited to, the recoverability of the carrying amount and estimated useful lives of long-lived assets, allowance for accounts receivable, realizable values for inventories, valuation allowance of deferred tax assets, purchase price allocation of its acquisitions, valuation of derivative financial instruments, valuation of available for sale security, and share-based compensation expenses. Changes in facts and circumstances may result in revised estimates. Actual results could differ from these estimates.

Foreign Currency

The accompanying consolidated financial statements are presented in United States dollars (“US$”). The functional currency of the Company is US$, while that of the Company’ subsidiaries operating in the PRC is Renminbi (“RMB”), as determined based on the criteria of FASB ASC 830 “Foreign Currency Matters”.

Assets and liabilities of non-U.S. subsidiaries are translated into U.S. dollars at the noon buying rate certified by the Federal Reserve Bank of New York on June 30, 2010. Income and expense items are translated at average exchange rates prevailing during the quarter. The resulting translation adjustments are recorded as a component of shareholders’ equity. Gains and losses from foreign currency transactions are included in net income.

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

Revenues represent the invoiced value of goods sold and are recognized upon the shipment of goods to customers. The product sales price stated in the sales contract or purchase order is final and not subject to adjustment. Revenues are recognized pursuant to FASB ASC 605 “Revenue Recognition”, when all of the following criteria are met:

●

Persuasive evidence of an arrangement exists,

●

Delivery has occurred or services have been rendered,

●

The seller’s price to the buyer is fixed or determinable, and

●

Collectability is reasonably assured.

Revenue is recognized net of all value-added taxes imposed by governmental authorities and collected from customers concurrent with revenue-producing transactions.

Cost of Sales

Cost of sales includes direct and indirect production costs, as well as freight in and handling costs for products sold.

Selling and Marketing Expenses

Selling and marketing expenses include the costs of selling merchandise, including preparing the merchandise for sale, such as picking, packing, warehousing and order charges. All shipping and handling are expensed as incurred and outbound freight is not billed to customers.

Advertising Costs

The Company expenses advertising costs as incurred. Point of sale materials are accounted for as inventories and are charged to expense as utilized.

Research and Development Costs

Research and development costs are expensed as incurred.

FASB ASC 805 “Business combinations” requires the recognition of tangible and intangible assets that result from or are to be used in research and development activities as assets, irrespective of whether the acquired assets have an alternative future use. Acquired In-Progress Research & Development (IPR&D) assets are required to be measured at their acquisition-date fair value. Uncertainty about the outcome of an individual project does not affect the recognition of an IPR&D asset, but is reflected in its fair value.

Comprehensive Income

Comprehensive income is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, items that are required to be recognized under current accounting standards as components of comprehensive income are required to be reported in a financial statement that is presented with the same prominence as other financial statements. The Company’s comprehensive income includes net income and foreign currency translation adjustments.

Stock-Based Compensation

Stock-based compensation includes 1) stock options and common stock awards granted to employees and directors for services, and are accounted for under FASB ASC 718 “Compensation - Stock Compensation”, and 2) common stock awards granted to consultants which are accounted for under FASB ASC 505-50 “Equity – Equity-Based Payments to Non-Employees”.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

All grants of common stock awards and stock options to employees and directors are recognized in the financial statements based on their grant date fair values. The Company has elected to recognize compensation expense using the straight-line method for all common stock awards and stock options granted with service conditions that have a graded vesting schedule, with a corresponding charge to additional paid-in capital.

Common stock awards are granted to directors for services provided. The vested portions of common stock awards granted but not yet issued are recorded in Common Stock to be Issued until issuance.

Common stock awards issued to consultants represent common stock granted to non-employees in exchange for services at fair value. The measurement dates for such awards are set at dates that the contracts are entered into as the awards are non-forfeitable and vest immediately. The measurement date fair value is then recognized over the service period as if the Company has paid cash for such service. The Company does not have significant grants to consultants for any of the period presented.

The Company estimates fair value of common stock awards based on the number of shares granted and the quoted price of the Company’s common stock on the date of grant.

The fair value of stock options is estimated using the Black-Scholes model. The Company’s expected volatility assumption is based on the historical volatility of the Company’s stock. The expected life assumption is presumed to be the mid-point between the vesting date and the end of the contractual term, as is permitted for “plain vanilla” employee stock options. The risk-free interest rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

FASB ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in the subsequent period if actual forfeitures differ from initial estimates. Forfeiture rate is estimated based on historical and future expectation of employee turnover rate and are adjusted to reflect future change in circumstances and facts, if any. Share-based compensation expense is recorded net of estimated forfeitures such that expense was recorded only for those stock options and common stock awards that are expected to vest.

Income Taxes

The Company accounts for income taxes following the liability method pursuant to FASB ASC 740 “Income Taxes”. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if, based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in income in the period that includes the enactment date.

The Company accounts for uncertainty in income taxes in accordance with ASC 740-10 “Income Taxes-Overall”. The Company has elected to classify interest and penalties related to an uncertain position, if and when required, as part of interest expenses and other expenses, respectively, in the consolidated statements of income and comprehensive income.

Value-Added Tax (“VAT”)

Enterprises or individuals, who sell commodities, engage in repair and maintenance or import or export goods in the PRC are subject to a value-added tax in accordance with the PRC laws. The value-added tax’s standard rate is 17% of the gross sales price and the Company records its revenue net of VAT. A credit is available whereby VAT paid on the purchases of semi-finished products or raw materials used in the production of the Company’s finished products can be used to offset the VAT due on the sales of the finished products.

Segment Reporting

The Company has two operating segments based on its major lines of businesses: manufacturing and distribution. Each operating segment derives its revenues from the sale of products or services, respectively and each is the responsibility of a group of senior management of the Company who has knowledge of product and service specific operational risks and opportunities. The Company’s chief operating decision maker reviews and evaluates separate sets of financial information for decisions regarding resources allocation and performance assessments.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Cash and Cash Equivalents

Cash and cash equivalents consist of cash on hand and bank deposits with original maturities of three months or less, which are unrestricted as to withdrawal and use.

Restricted Cash

Restricted cash represents amounts held by a bank as security for bank acceptance notes and therefore is not available for the Company’s use. The restriction on cash is expected to be released within the next twelve months.

Accounts Receivable

Accounts receivable are carried at net realizable value. An allowance for doubtful accounts is recorded in the period when loss is probable based on an assessment of specific evidence indicating troubled collection, historical experience, accounts aging and other factors. An account receivable is written off after all collection effort has ceased.

Debt Issuance Costs

Debt issuance costs represent the incurred costs directly attributable to the issuance of the convertible notes. These costs, presented as non-current assets, are deferred and amortized ratably using the effective interest method from the debt issuance date over the earliest redemption date of the convertible notes. If the notes are converted prior to the debt maturity date, the unamortized debt issuance costs will be transferred to equity immediately upon occurrence of such an event.

Inventories

Inventories are stated at the lower of cost or market value. Cost is determined by the weighted average method. Costs of raw materials and consumables and packaging materials are based on purchase costs while costs of work-in-progress and finished goods comprise direct materials, direct labor and an allocation of manufacturing overhead costs.

Recurring agricultural costs include costs relating to irrigation, fertilizing, seedling, utility, farming wages and other ongoing crop and land maintenance activities. Recurring agricultural costs are capitalized as inventory and cease to be accumulated when the crops have reached maturity and ready to be harvested. Any recurring agricultural costs incurred subsequent to the crops reaching maturity are expensed as incurred. Non recurring agricultural costs, primarily comprising soil improvements and other long-term crop growing costs that benefit multiple harvests, are deferred and amortized over the estimated production period.

Fair Value of Financial Instruments

FASB ASC 820 “Fair Value Measurements and Disclosures” establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:

●

Level 1 - defined as observable inputs such as quoted prices in active markets;

●

Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

●

Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, notes receivable, short-term and long-term bank loans, accounts payable, notes payable and other payables, approximate their fair values because of the short maturity of these instruments. The convertible notes are initially recognized at fair value upon issuance and subsequently accreted to the redemption value using the effective interest rate method, with any accrued and unpaid interest included under other payables and accrued expenses.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Construction in Progress

Construction in progress represents direct costs of construction or acquisition, interest and design fees incurred. Capitalization of these costs ceases and the construction in progress is transferred to property, plant and equipment when substantially all the activities necessary to prepare the assets for their intended use are completed. No depreciation is provided until it is completed and ready for intended use.

The Company accounts for interest capitalization in accordance with FASB ASC 835 "Interest". Interest costs are capitalized if they are incurred during the acquisition, construction or production of a qualifying asset and such costs could have been avoided if expenditures for the assets have not been made. Capitalization of interest costs commences when the activities to prepare the asset are in progress and expenditures and borrowing costs are being incurred. Interest costs are capitalized until the assets are ready for their intended use.

Land Use Rights

According to the PRC laws, the government owns all the land in the PRC. Companies or individuals are authorized to possess and use the land only through land use rights granted by the PRC government. Land use rights are being amortized using the straight-line method over the lease term ranging from 40 to 50 years.

Property, Plant and Equipment

Property, plant and equipment are carried at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line method. Estimated useful lives of the property, plant and equipment are as follows:

Buildings	40 years
Machinery and equipment	10 years
Motor vehicles	5 years
Office equipment	5 years
Other equipment	5 years
Leasehold improvements	Shorter of 10 years or the lease term

The cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the statement of income. The cost of maintenance and repairs is charged to the statement of income as incurred, whereas significant renewals and betterments are capitalized.

Other Intangible Assets

Other intangible assets include product licenses, trademarks, patents and proprietary technologies, which are stated at acquisition cost less accumulated amortization. Amortization expense is recognized using the straight-line method over the estimated useful life. Proprietary technologies are recorded as an intangible asset only if regulatory approval from SFDA has been obtained and for which the re-registration of the proprietary technologies with the SFDA by the Company in its name is determined to be reasonably assured or perfunctory. The amortization of such intangible assets will not commence until the technology has been re-registered with the SFDA and hence ready for its intended use. The cost of the product licenses are amortized over their licensed period of 2 to 12 years; the cost of trademarks are amortized over their registered period of 2 to 10 years; the cost of patents are amortized over their protection period of 7 to 20 years and the cost of proprietary technologies is amortized over its protection period of 10 years. The weighted-average amortization period of product licenses, trademarks, patents and proprietary technologies are 7.56 years, 6.40 years, 12.62 years and 9.42 years, respectively.

Goodwill

Goodwill and other intangible assets are accounted for in accordance with the provisions of FASB ASC 805 and FASB ASC 350 “Intangibles - Goodwill and Other”. Under FASB ASC 805, goodwill is measured as the excess of a over b below:

a.	The aggregate of the following:

The consideration transferred measured in accordance ASC 805, which generally requires acquisition-date fair value.

The fair value of any non-controlling interest in the acquiree.

In a business combination achieved in stages, the acquisition-date fair value of the acquirer’s previously held equity interest in the acquiree.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

b.	The net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed measured in accordance with FASB ASC 805.

Other intangible assets are separately recognized from goodwill if the benefit of the intangible asset is obtained through contractual or other legal rights, or if the intangible asset can be sold, transferred, licensed, rented, or exchanged, regardless of an intent to do so.

Under FASB ASC 350, goodwill, including any goodwill included in the carrying value of investments accounted for using the equity method of accounting, and certain other intangible assets deemed to have indefinite useful lives are not amortized.

Impairment

Finite-lived intangible assets are amortized over their respective useful lives and, along with other long-lived assets, are evaluated for impairment periodically whenever events or changes in circumstances indicate that their related carrying amounts may not be recoverable in accordance with FASB ASC 360, “Property, Plant and Equipment”.

In evaluating long-lived assets for recoverability, including finite-lived intangibles and property and equipment, the Company uses its best estimate of future cash flows expected to result from the use of the asset and eventual disposition in accordance with FASB ASC 360-10-15. To the extent that estimated future, undiscounted cash inflows attributable to the asset, less estimated future, undiscounted cash outflows, are less than the carrying amount, an impairment loss is recognized in an amount equal to the difference between the carrying value of such asset and its fair value. Assets to be disposed of and for which there is a committed plan of disposal, whether through sale or abandonment, are reported at the lower of carrying value or fair value less costs to sell.

No impairment loss is subsequently reversed even if facts and circumstances indicate recovery. There was no impairment loss recognized for the periods presented.

Investments

The Company applies FASB ASC 323 “Investments—Equity Method and Joint Ventures” in accounting for its equity investments. Under FASB ASC 323, the equity method of accounting is used for investments in entities in which the Company has the ability to exercise significant influence but does not own a majority equity interest or otherwise control. Cost method is used for investments over which the Company does not have the ability to exercise significant influence or control.

The Company monitors its investments for other-than-temporary impairment by considering factors including, but not limited to, current economic and market conditions, the operating performance of the investee companies including current earnings trends and other company-specific information. Any balance of equity method goodwill is not tested for impairment under the provisions of FASB ASC 350. Instead, equity method goodwill is tested for impairment together with the related investment as they are not separable.

Economic and Political Risks

The Company’s operations are conducted in the PRC. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC economy.

The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion, remittances abroad, rates and methods of taxation and price controls, among other things.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

The Company’s products are subject to price control by the PRC government. The maximum prices of the products are published by the PRC price administration authorities from time to time. Any changes in product pricing announced by the PRC price administration authorities affect future sales transactions.

Recently Issued Accounting Standards

In April 2010, the FASB issued Accounting Standards Update 2010-13 (ASU 2010-13), "Compensation—Stock Compensation (Topic 718)." This Update provides amendments to Topic 718 to clarify that an employee share-based payment award with an exercise price denominated in the currency of a market in which a substantial portion of the entity’s equity securities trades should not be considered to contain a condition that is not a market, performance, or service condition. Therefore, an entity would not classify such an award as a liability if it otherwise qualifies as equity. The amendments in ASU 2010-13 are effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2010. The provision of ASU 2010-13 are not expected to have a material effect on the financial position, results of operations or cash flows of the Company.

NOTE 3 - EARNINGS PER SHARE

Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding, excluding common shares to be delivered under a prepaid forward repurchase contract (3,712,700 shares) during the period. Diluted earnings per share is computed by dividing net income attributable to controlling interest as adjusted for the effect of dilutive potential common shares, if any, by the weighted average number of common shares and dilutive potential common shares outstanding during the period. The potential common stocks are stock options, common stock awards and convertible notes.

The following is a reconciliation of the numerator and denominator used in the calculation of basic and diluted earnings per share available to common shareholders.

	Three Months Ended June 30,				Six Months Ended June 30,
	2010		2009		2010		2009
Numerator:
Net income attributable to controlling interest	$	5,124,210	$	12,569,338	$	8,247,387	$	19,720,847
Interest expense on convertible securities, net of taxes		-		1,437,500		-		2,875,000
Amortization of financing costs, net of taxes		-		232,072		-		464,144
Net income, as adjusted	$	5,124,210	$	14,238,910	$	8,247,387	$	23,059,991

Denominator:
Weighted average shares outstanding – Basic		74,743,986		74,582,920		74,680,327		74,560,809
Effect of dilutive instruments:
Convertible notes		-		14,232,673		-		12,378,902
Common stock awards to be issued		1,113,087		-		822,162		-
Weighted average shares outstanding – Diluted		75,857,073		88,815,593		75,502,489		86,939,711

The calculation of weighted average common shares outstanding for the diluted earnings per share calculation excludes consideration of stock options for the three and six months ended June 30, 2010 and 2009 and convertible notes for the three and six months ended June 30, 2010, because the exercise of these options and conversion of the convertible notes would not have been dilutive for those periods due to the fact that the exercise prices were greater than the weighted average market price of our common stock for each period and the conversion of the convertible notes under the if-converted method would have been anti-dilutive for each period.

As more fully discussed in Note 13, the Company had certain convertible notes outstanding during the periods presented. The aggregate number of shares of common stock that could be issued in the future to settle these notes is deemed outstanding for the purposes of the calculation of diluted earnings per share. This approach, referred to as the if-converted method, requires that such shares be deemed outstanding regardless of whether the notes are then contractually convertible into the Company’s common stock. For this if-converted calculation, the interest expense and issuance costs (net of tax) attributable to these notes are added back to Net income attributable to controlling interest, reflecting the assumption that the notes have been converted.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

NOTE 4 - SEGMENT REPORTING

For the three and six months ended June 30, 2010 and 2009 the Company’s segments were as follows:

	Three Months Ended June 30,
	2010		2009
Manufacturing Segment
Revenue from pharmaceutical products	$	63,776,505		58,438,805
Revenue from nutraceutical products		9,934,088		9,523,090
Total manufacturing revenue		73,710,593		67,961,895
Total manufacturing costs		33,975,991		26,448,200
Interest (expense) income, net		(79,395)		17,258
Depreciation, depletion and amortization expense		1,220,088		1,254,961
Other operating expenses		26,867,611		19,642,184
Income tax expense		2,395,850		3,826,719
Operating income of manufacturing segment		9,171,658		16,807,089

	Three Months Ended June 30,
	2010				2009

Distribution Segment
Distribution revenue		$	3,585,619			$	3,260,142
Distribution costs			3,479,869				3,146,723
Interest income, net			18,092				32,476
Depreciation, depletion and amortization expense			9,550				9,140
Equity in earnings from unconsolidated entities			740,345				601,970
Other operating expenses			347,772				383,530
Income tax expense (benefit)			-				(91,161	)
Operating income of distribution segment			506,865				446,356

Reconciliation to Consolidated Net Income Available for Common Shareholders:
Total net operating income, as defined, for reportable segments			9,678,523				17,253,445
Unallocated			(4,554,313	)			(4,684,107	)
Consolidated Net Income Available for Common Shareholders		$	5,124,210			$	12,569,338

	Six Months Ended June 30,
	2010		2009

Manufacturing Segment
Revenue from pharmaceutical products	$	104,641,586		93,118,274
Revenue from nutraceutical products		19,599,791		18,435,483
Total manufacturing revenue		124,241,377		111,553,757
Total manufacturing costs		56,367,559		41,719,038
Interest (expense) income, net		(163,584)		20,297
Depreciation, depletion and amortization expense		2,415,444		2,493,343
Other operating expenses		44,833,832		33,300,054
Income tax expense		3,835,406		6,293,854
Operating income of manufacturing segment		16,625,552		27,767,765

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Six Months Ended June 30,
	2010		2009

Distribution Segment
Distribution revenue	$	6,804,603	$	5,745,470
Distribution costs		6,601,348		5,536,223
Interest income, net		31,662		107,419
Depreciation, depletion and amortization expense		18,925		16,903
Equity in earnings from unconsolidated entities		1,344,795		1,095,873
Other operating expenses		621,850		536,541
Income tax expense or (benefit)		-		(88,532)
Operating income of distribution segment		938,937		947,627

Reconciliation to Consolidated Net Income Available for Common Shareholders:
Total net operating income, as defined, for reportable segments		17,564,489		28,715,392
Unallocated		(9,317,102)		(8,994,545)
Consolidated Net Income Available for Common Shareholders	$	8,247,387	$	19,720,847

NOTE 5 - INVENTORIES

Inventories are summarized as follows:

	JUNE 30, 2010		DECEMBER 31, 2009
Raw materials	$	7,615,768	$	4,599,700
Work in progress		3,183,830		2,407,927
Finished goods		8,238,126		3,043,926
Total inventories		19,037,724		10,051,553
Less: provision against slow-moving inventories		(21,146)		(35,842	)
Inventories, net	$	19,016,578	$	10,015,711

As of June 30, 2010 and December 31, 2009, raw materials included capitalized agricultural costs of $176, 600 and nil, respectively.

NOTE 6 - LAND USE RIGHTS

Land use rights consist of the following:

	JUNE 30, 2010		DECEMBER 31, 2009
Cost of land use rights	$	160,838,333	$	160,165,545
Less: Accumulated amortization		(8,243,338)		(6,561,349	)
Land use rights, net	$	152,594,995	$	153,604,196

As of June 30, 2010 and December 31, 2009, the net book value of land use rights pledged as collateral was $25,319,125 and $48,101,071, respectively. See Note 12.

Amortization expense for the quarters ended June 30, 2010 and 2009 was $825,540 and $786,235, respectively. Amortization expense for the six months ended June 30, 2010 and 2009 was $1,649,353 and $1,570,865, respectively.

NOTE 7 - CONSTRUCTION IN PROGRESS

Construction in progress as of June 30, 2010 and December 31, 2009 was $29,324,123 (inclusive of capitalized interest of $1,529,542) and $28,975,386 (inclusive of capitalized interest of $816,392), respectively. Construction in progress represents the construction for production lines and buildings. The Group capitalizes interest as a component of construction in progress in accordance with ASC 835. Total interest costs incurred for the three months ended June 30, 2010 and 2009 amounted to $1,826,641 and $1,783,522, respectively and total interest costs incurred for the six months ended June 30, 2010 and 2009 amounted to $3,823,266 and $3,568,078, respectively.

Total interest costs capitalized as part of construction in progress for the three months ended June 30, 2010 and 2009 amounted to $360,310 and nil, respectively and for the six months ended June 30, 2010 and 2009 amounted to $713,150 and nil, respectively.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

NOTE 8 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consist of the following:

	JUNE 30, 2010		DECEMBER 31, 2009
At cost:
Buildings	$	91,938,573	$	91,565,622
Machinery and equipment		21,796,574		21,016,658
Motor vehicles		1,541,687		1,535,238
Office equipment		2,233,021		2,157,528
Other equipment		1,657,892		610,945
		119,167,747		116,885,991
Less : Accumulated depreciation
Buildings		(7,791,456)		(6,600,971	)
Machinery and equipment		(13,223,024)		(12,483,002	)
Motor vehicles		(1,237,455)		(1,130,968	)
Office equipment		(1,227,910)		(1,037,234	)
Other equipment		(242,432)		(165,551	)
		(23,722,277)		(21,417,726	)
Property, plant and equipment, net	$	95,445,470	$	95,468,265

As of June 30, 2010 and December 31, 2009, the net book value of property, plant and equipment pledged as collateral for bank loans were $6,741,934 and $13,615,710. See Note 12.

Depreciation expense for the quarters ended June 30, 2010 and 2009 was $1,208,865 and $1,141,903, respectively. Depreciation expense for the six months ended June 30, 2010 and 2009 was $2,386,870 and $2,299,681, respectively.

NOTE 9 - OTHER INTANGIBLE ASSETS, NET

Other intangible assets are summarized as follows:

	JUNE 30, 2010		DECEMBER 31, 2009
At cost:
Product licenses	$	15,589,656	$	15,524,443
Trademarks		10,629,376		10,584,914
Patents		4,828,301		4,808,103
Proprietary technology		283,550		282,364
Software		74,133		73,822
		31,405,016		31,273,646
Less: Accumulated amortization
Product licenses	$	(7,807,272)	$	(6,396,185	)
Trademarks		(5,010,610)		(4,168,125	)
Patents		(2,160,324)		(1,935,171	)
Proprietary technology		(82,807)		(67,468	)
Software		(14,900)		(11,143	)
		(15,075,913)		(12,578,092	)
Other intangible assets, net	$	16,329,103	$	18,695,554

Amortization expense for the quarters ended June 30, 2010 and 2009 was $1,220,018 and $1,282,010, respectively. Amortization expense for the six months ended June 30, 2010 and 2009 was $2,437,484 and $2,575,007, respectively.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

NOTE 10 - INVESTMENTS IN AND ADVANCES TO UNCONSOLIDATED ENTITIES

Long-term investments and advances include our equity investment in Aoxing Pharmaceutical Company, Inc. (“AXN”), Nuo Hua Affiliate and Hezhou Jinji Color Printing Co Ltd. (“Jinji”). AXN is a PRC-based pharmaceutical company, listed on the NYSE AMEX, specializing in the research, development, manufacture and distribution of narcotic and pain-management products in the PRC. Nuo Hua Affiliate maintains a significant presence in pharmaceutical wholesale and retail distribution in the PRC. Jinji is a color printing company focusing on the printing of external packaging materials. Long-term investments are accounted for using the equity accounting method.

As of June 30, 2010, the Company owns a 36.13% equity interest in AXN through an initial $18 million direct investment of its common stock in April 2008 and a subsequent conversion of a promissory note into additional common stock in August 2009. The promissory note represents an advance of RMB30 million to AXN in May 2008. The note bears interest at a rate of 8% payable quarterly in arrears with an initial term of one year which was subsequently extended for additional three months. Upon conversion, the balance of such advance was reclassified to investment.

The Company owns a 30% equity interest in Nuo Hua Affiliate through the acquisition of Nuo Hua in October 2008 and the Company owns a 40% equity interest in Jinji through the acquisition of GLP in April 2006.

The cost of investments in excess of our estimate of the underlying equity in net assets at the time of the investments was goodwill of $1,369,799.

The following table summarizes the long-term investments and advances as of June 30, 2010 and December 31, 2009:

	JUNE 30, 2010		DECEMBER 31, 2009
Cost of investments:
AXN	$	22,759,612	$	22,759,612
Nuo Hua Affiliate		32,999,023		32,999,023
Jinji		86,067		86,067
Share of equity income (loss):
AXN		(3,310,270)		(1,909,244	)
Nuo Hua Affiliate		4,761,692		3,260,590
Jinji		48,943		45,480
Advances:
AXN		(3,300)		3,300
Jinji		99,281		81,059
Long-term investments and advances	$	57,441,048	$	57,325,887

The advances to AXN and Jinji were unsecured, non-interest bearing and repayable on demand.

For the three and six months ended June 30, 2010 and 2009, the Company’s equity in earnings from above unconsolidated entities was as follows:

	Three Months Ended June 30,
	2010			2009

Equity (income) - Nuo Hua Affiliate		$	(740,345)		$	(601,970)
Equity loss - AXN			913,177			775,272
Equity (income) - Jinji Printing			(2,033)			(44)
Total equity in loss from unconsolidated entities		$	170,799		$	173,258

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Six Months Ended June 30,
	2010			2009

Equity (income) - Nuo Hua Affiliate	$	(1,344,795	)	$	(1,095,873)
Equity loss - AXN		1,401,026			832,797
Equity (income) - Jinji Printing		(2,905)			(1,460)
Total equity in (earnings) loss from unconsolidated entities	$	53,326		$	(264,536)

As of June 30, 2010 and December 31, 2009, the value based on quoted market price and the carrying amount of the investment in AXN is as follows:

	June 30, 2010		December 31, 2009
Investment in AXN based on quoted market price	$	54,732,800	$	33,578,405
Carrying amount of investment in AXN	$	19,449,342	$	20,850,368

NOTE 11 - OTHER LONG-TERM ASSETS

	JUNE 30, 2010		DECEMBER 31, 2009
Payment for long-term supply contract	$	7,500,808	$	7,469,432
Deposits for long-term assets		466,976		439,654
Total other long-term assets	$	7,967,784	$	7,909,086

Payment of the long-term supply contract represents a payment for a long-term supply contract with a third party to secure the supply of Xanthoceras Sorbifolia Bge (“XSB”), a major raw material of a subsidiary of the Company. The Company expects such supply to start from year four of the contract as XSB is a fruit from certain plant which requires a three year period to mature. The contract expires after 10 years while the Company is entitled to renewal with terms to be negotiated. Under the contract, the Company is entitled to a supply price at fair value when delivered. The payment will be amortized to inventory upon delivery of the raw material. The Company assesses the impairment of the payment as of each balance date. As of June 30, 2010, no impairment was recognized.

Deposits for long term assets are refundable deposits to acquire land use rights located in the PRC. The long-lived assets to be acquired will be for use in the expansion of some of the Company's current manufacturing facilities and are not intended for resale by the Company. The deposits will be reclassified to the respective accounts under the long-lived assets upon the transfers of legal title.

NOTE 12 - DEBT

Short-term bank loans are obtained from local banks. All the short-term bank loans are repayable within one year and are secured by property, plant and equipment and land use rights owned by the Company. See Notes 6 and 8.

Long-term loans include a mortgage loan that bears interest on daily balances at 2.50% per annum below HSBC HKD best lending rate and is repayable over 15 years. The principal amount of long-term loans is not payable until the end of the term.

Interest expense for all outstanding debt excluding the convertible notes was $145,346 and $113,950 for the three months ended June 30, 2010 and 2009, respectively. Interest expense for all outstanding debt excluding the convertible notes was $294,472 and $228,934 for the six months ended June 30, 2010 and 2009, respectively.

NOTE 13 - CONVERTIBLE NOTES

On July 15, 2008, the Company closed a private offering and issued $115 million aggregate principal amount of 5.00% Convertible Senior Notes due 2015 (the “Notes”). The Notes were sold to qualified institutional buyers in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended. The net proceeds from the sale of the Notes were approximately $110,474,993, after deducting the placement agents’ commission and offering expenses payable by the Company.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

The following is a brief summary of certain terms of this offering.

●

Total offering is $115,000,000 aggregate principal amount of 5.00% Convertible Senior Notes due on July 15, 2015.

●

Interest at 5.00% per year, payable semiannually in arrears in cash.

●

The Notes are convertible, at the option of the holder, at any time prior to the close of business on the second business day preceding the maturity date based on an initial conversion rate of 107.6195 shares per $1,000 principal amount of Notes, which represents an initial conversion price of approximately $9.29 per share. (See below)

●

The conversion rate is subject to certain adjustments. In particular, holders who convert their Notes in connection with certain events of fundamental changes, as defined pursuant to the convertible notes agreement, may be entitled to a make whole premium in the form of additional shares of our common stock.

●

The initial conversion rate may also be adjusted on January 15, 2009 if the volume weighted average price (“VWAP”) of common stock for each of the 30 consecutive trading days ended on January 15, 2009 is less than $8.08 per share. In such an event, the conversion rate will be increased as a one-time conversion price adjustment such that the conversion price as adjusted would represent the greater of (1) 115.0% of such arithmetic average of the daily VWAP and (2) $8.08.

●

Holders may require the Company to repurchase all or a portion of their Notes on July 15, 2013 for cash at a price equal to 100% of the principal amount of the notes to be purchased, plus accrued and unpaid interest, if any, up to, but excluding, the repurchase date.

●

If a fundamental change event occurs, holders will have the right to require the Company to repurchase for cash all or any portion of their notes. The fundamental change purchase price will be 100% of the principal amount of the Notes to be purchased plus accrued and unpaid interest, if any, up to, but excluding, the fundamental change repurchase date.

●

The Notes are unsecured, unsubordinated obligations and rank equal in right of payment to all of the Company’s existing and future unsecured and unsubordinated indebtedness. The Notes will be effectively subordinated to all of the Company’s existing and future secured indebtedness.

Notes issuance costs incurred by the Company that were directly attributable to the issuance of the Notes were deferred and are charged to the consolidated statements of income and comprehensive income using the effective interest rate method over the term of the Notes.

The Company has determined that the conversion feature embedded in the Notes is not required to be bifurcated and accounted for as a derivative pursuant to FASB ASC 815 “Derivatives and Hedging”, since the embedded conversion feature is indexed to the Company’s own stock and would be classified in shareholders’ equity if it was a free-standing instrument. The holder’s put rights qualify as an embedded derivative, but bifurcation of such is not required since it is considered to have economic characteristic and risks that are clearly and closely related to those of the debt host.

On the date of issuance of the Notes, no portion of the proceeds was attributable to the beneficial conversion feature (“BCF”) since the conversion price of the Notes exceeded the market price of the Company’s common stock. Furthermore, no contingent BCF exists from the one time conversion rate adjustment based on VWAP, as the adjustment is subject to a floor of $8.08, which equals market price of the Company’s common stock on the issuance date of the Notes.

The VWAP of our common stock for each of the 30 consecutive trading days ending on January 15, 2009 was $6.02 per share and as such, the initial conversion price of $9.29 per share was adjusted to $8.08 on January 15, 2009.

The effective interest rate on the Notes for the three months and for the six months ended June 30, 2010 and 2009 was 5.945%.

The amount of interest cost recognized for the three months ended June 30, 2010 and 2009 was $1,437,500 for the six months ended June 30, 2010 and 2009 was $2,875,000.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

NOTE 14 - PREPAID FORWARD SHARES REPURCHASE TRANSACTION

In connection with the offering of the Notes, the Company entered into a prepaid forward repurchase contract with an affiliate of the lead placement agent (“Merrill affiliate”). Pursuant to the prepaid forward repurchase contract, the Company paid approximately $30 million to the Merrill affiliate to fund the purchase of 3.7 million shares of common stock for settlement at or about maturity of the Notes, which will occur on July 15, 2015. The forward shares purchase transaction was also intended to reduce the potential dilution of common stock that would result from the conversion of the Notes into shares of common stock.

The $30 million cost of the forward stock repurchase transaction qualifies as an equity transaction and was separately presented under shareholders’ equity in the balance sheet without subsequent recognition of changes in fair value. The prepaid forward repurchase contract contains an embedded equity forward derivative that is contingently cash settleable based on certain events. The contingent cash settlement feature was bifurcated from the prepaid forward repurchase contract but its value was insignificant for any of the periods presented.

The Company is potentially subject to significant concentration of credit risk with respect to the prepaid forward repurchase contract. The fact that the Merrill affiliate has merged with Bank of America reduced the bankruptcy and default risk. The Company will closely monitor the third depositary and may request early settlement of the contract prior to the maturity of the Notes.

NOTE 15 - SHAREHOLDERS’ EQUITY

Preferred Stock

The Company had 1,000,000 shares of Series A preferred stock (“Series A”) issued and outstanding. Pursuant to the terms of the Series A, the holder holds aggregate voting power equal to 25% of the combined voting power of common stock and preferred stock. The percentage of voting power represented by the Series A cannot be diluted by the issuance of additional shares of common stock. The Series A has a liquidation preference equal to its initial issue price that will be paid to the holders of the Series A upon liquidation, dissolution or winding up and prior to any distributions being made to holders of common stock.

Common Stock

Stock-Based Compensation

At the Annual Shareholders’ Meeting held on October 21, 2006, the shareholders of the Company approved the stock incentive plan (the “2006 Plan”), which allows the Company’s board of directors, at its discretion, to offer stock options and common stock awards to participants (employees, directors and consultants) of the Company.

The Company has reserved 5,000,000 shares of common stock for issuance upon the exercise of stock options and common stock awards granted under the 2006 Plan. The term of the options granted under the 2006 Plan should be no more than 10 years from the grant date. Options will be granted with an exercise price not less than the fair market value of a share of common stock on the date of the grant.

Common Stock Awards issued to consultants and employee directors

Such awards are issued to consultants as partial payment in connection with the consulting services rendered or to be rendered, or to directors as compensation for participating in the Company’s board meetings. Number of shares granted and expenses recognized were insignificant during the periods presented.

In connection with common stocks awards described above, the Company recorded Common Stocks to be issued for vested but yet to be issued shares. Number of shares to be issued was insignificant during the periods presented.

Stock Options and Common Stock Awards issued to Employees

Stock options and common stock awards granted to employees vest over a five year service period using a graded vesting schedule of 20% per fully completed year (based on each subsequent one-year anniversary of the date of grant). Compensation expense for all stock options and common stock awards granted is recognized over the awardee’s respective requisite service period.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Stock options

The Company calculated the estimated fair value of the options of the grant date using the Black-Scholes Option Pricing Model with the following assumptions:

Grant Date	April 10, 2009			November 25, 2008			April 9, 2008			August 20, 2007			April 20, 2007

Risk-free interest rates		2.33	%		2.41	%		2.93	%		4.45	%		4.59	%
Expected term		6.5			6.5			6.5			6.5			6.5
Expected volatility		65.70	%		64.81	%		56.89	%		71.71	%		74.69	%
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%
Fair value of share option		2.64			3.34			4.81			5.87			7.44

The model requires the input of subjective assumptions including the expected stock price volatility, and the expected dividend yield. The Company uses historical experience of employee turnover and future expectation to estimate forfeiture rate. For expected volatilities, the Company has made reference to historical volatilities of the Company’s stock. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury Bills yield in effect at the time of grant.

The Company recorded $474,638 and $519,643 compensation cost for the three months ended June 30, 2010 and 2009, respectively and $949,276 and $1,009,500 for the six months ended June 30, 2010 and 2009, respectively, with corresponding credits to additional paid-in capital. Compensation cost of all stock option awards are recorded in general and administrative expenses.

The expected forfeiture rate of the stock options granted as of June 30, 2010 is 0%.

Common Stock Awards

On April 10, 2009 and April 8, 2010, the Compensation Committee of the Board of Directors of the Company approved the grant of common stock awards to the Company’s executive officer and certain senior management members. Common stocks awards granted vest over a five year service period. Compensation expense is recognized for the fair value of common stocks on the grant date on a straight-line basis over five years, the requisite service period of the awards. The number of shares granted and the grant date market price of the Company’s common stock determines the fair value of the common stocks awards under the 2006 Plan.

The expected forfeiture rate of the common stock awards granted as of June 30, 2010 is 0%.

The Company recorded general and administrative expenses of $227,954 and $117,999 in connection with such awards for the three months ended June 30, 2010 and 2009, respectively and $331,553 and $117,999 for the six months ended June 30, 2010 and 2009, respectively.

Statutory Reserves

In accordance with the PRC Regulations on Enterprises with Foreign Investment, an enterprise established in the PRC with foreign investment is required to provide for certain statutory reserves, namely (i) General Reserve Fund, (ii) Enterprise Expansion Fund and (iii) Staff Welfare and Bonus Fund, which are appropriated from net profit as reported in the enterprise’s PRC statutory accounts. A wholly-owned foreign enterprise (“WOFE”) is required to allocate at least 10% of its annual after-tax profit to the General Reserve Fund until the balance of such fund has reached 50% of its respective registered capital. A non- wholly-owned foreign invested enterprise is permitted to provide for the above allocation at the discretion of its board of directors. Appropriations to the Enterprise Expansion Fund and Staff Welfare and Bonus Fund are at the discretion of the board of directors for all foreign invested enterprises.

The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends.

As a result, $23,757,901 has been appropriated to the accumulated statutory reserves (included in the retained earnings) by the Company’s PRC subsidiaries as of June 30, 2010 and December 31, 2009.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

NOTE 16 - COMMITMENTS AND CONTINGENCIES

As of June 30, 2010, the Company had entered into capital commitments for the manufacturing facilities under construction in the People’s Republic of China and purchase commitments for the purchase of raw materials. The Capital commitments and purchase commitments were $11,411,652 and $1,770,359 within one year and $8,615,574 and nil after one year but within five years, respectively. In addition, the Company had advertisement contract commitments of $17,961,196 for the next 12 months and R&D commitments of $5,052,206 for the next 24 months as of June 30, 2010.

Effective from January 1, 2007, the Company adopted FASB ASC 740-10, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the tax return. As of June 30, 2010, the Company has recorded an unrecognized tax benefit of $3,871,701.

As of June 30, 2010, the Company has no significant litigation claims. Also, the Company does not have significant operating-lease commitments as of June 30, 2010.

NOTE 17 – TAXES

The Group's effective tax rates are 32% and 23% for the three months ended June 30,2010 and 2009, respectively and are 34% and 24% for the six months ended June 30, 2010 and 2009, respectively. The increase in effective tax rate is mainly due to a decrease in profits before tax relative to permanent differences, unrecognized tax benefits and change in valuation allowance. The Group has total income tax expense of $2,395,850 for the three months ended June 30, 2010 and $4,211,780 for the six months ended June 30, 2010. The Group continues to conduct most of its business through its major PRC subsidiaries whose applicable income tax rate is 15%. A full valuation allowance is recorded for deferred tax assets of those entities within the group that continue to be in a cumulative loss position. The Group recorded a current tax expense of $2,505,489 for the three months ended June 30, 2010 of which $379,329 is related to an increase in unrecognized tax benefits and $4,318,381 for the six months of which $755,703 is related to an increase in unrecognized tax benefits. The Company recorded cumulative interests of $189,290 and a penalty of $440,000 as of June 30, 2010.

NOTE 18 - EMPLOYEE DEFINED CONTRIBUTION PLAN

Full time employees of the Company’s subsidiaries in the PRC participate in a government-mandated defined contribution plan pursuant to which certain pension benefits, medical care, unemployment insurance, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the PRC subsidiaries of the Company make contributions to the government for these benefits based on 41% of the employees’ salaries. The Company’s PRC subsidiaries have no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $262,440 and $238,321 for the three months ended June 30, 2010 and 2009, respectively and $479,178 and $463,234 for the six months ended June 30, 2010 and 2009, respectively and are included in general and administrative expenses.

NOTE 19 - SUBSEQUENT EVENTS

There were no significant subsequent events occurred.

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the information contained in the condensed consolidated financial statements of the Company and the notes thereto appearing elsewhere herein and in conjunction with the Management’s Discussion and Analysis set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009. Readers should carefully review the risk factors disclosed in the Company’s Form 10-K for the year ended December 31, 2009 filed by the Company with the Securities and Exchange Commission (SEC).

As used in this report, the terms “Company,” “we,” “our,” “us,” and “AOB” refer to American Oriental Bioengineering, Inc., a Nevada corporation.

PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as “anticipate,” “expect,” “intend,” “plan,” “will,” “we believe,” “AOB believes,” “management believes” and similar language. The forward-looking statements are based on the current expectations of AOB and are subject to certain risks, uncertainties and assumptions, including those set forth in the discussion under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this report. Actual results may differ materially from results anticipated in these forward-looking statements. We base the forward-looking statements on information currently available to us, and we assume no obligation to update them.

Investors are also advised to refer to the information in our previous filings with the SEC, especially on Forms 10-K, 10-Q, and 8-K, in which we discuss in more detail various important factors that could cause actual results to differ from expected or historic results. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factors to be an exhaustive statement of all risks and uncertainties or potentially inaccurate assumptions.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

This section should be read together with the Summary of Significant Accounting Policies included as Note 3 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2009.

RECENT ACCOUNTING PRONOUNCEMENT

A description of recent accounting pronouncements is set forth under “Recently Issued Accounting Standards” in Note 2 of the Notes to the Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q, and such description is incorporated herein by reference. Such description contains all of the information required with respect thereto.

RESULTS OF OPERATIONS – THREE MONTHS ENDED JUNE 30, 2010 AS COMPARED TO THREE MONTHS ENDED JUNE 30, 2009

The following table sets forth the amounts and the percentage relationship to revenues of certain items in our condensed consolidated statements of income for the quarters ended June 30, 2010 and 2009:

	Three Months Ended June 30,				Three Months Ended June 30,
	2010		2009		2010		2009

Revenues	$	77,296,212		71,222,037		100%		100%
Cost of sales		37,455,860		29,594,923		48		42
GROSS PROFIT		39,840,352		41,627,114		52		58

Selling and marketing expenses		11,505,462		9,396,129		15		13
Advertising costs		9,217,247		7,779,936		12		11
Research and development costs		3,250,882		809,584		4		1
General and administrative expenses		5,158,104		4,026,425		7		6
Depreciation and amortization		1,622,989		1,623,556		2		2
Total operating expenses		30,754,684		23,635,630		40		33

INCOME FROM OPERATIONS		9,085,668		17,991,484		12		25
Equity in earnings (loss) from unconsolidated entities		(170,799)		(173,258)		0		0
Interest expense, net		1,371,246		1,620,069		2		2
Other expenses, net		30,039		16,329		0		0
INCOME BEFORE INCOME TAX		7,513,584		16,181,828		10		23
Income tax		2,395,850		3,735,558		3		5
NET INCOME		5,117,734		12,446,270		7		18
Net loss attributable to non-controlling interest		6,476		123,068		0		0
NET INCOME ATTRIBUTABLE TO CONTROLLING INTEREST	$	5,124,210		12,569,338		7%		18%
EARNINGS PER COMMON SHARE
Basic	$	0.07		0.17
Diluted	$	0.07		0.16

Revenues

Revenues for the second quarter of 2010 were $77,296,212, an increase of $6,074,175, or 9% compared to revenues in the same period of 2009. We classify our revenues in two segments: Manufacturing revenue, which comprises sales by our subsidiaries of our pharmaceutical and nutraceutical products, and Distribution revenue. Revenues by segments and product categories were as follows:

	Three Months Ended June 30,				Increase/		Increase/
	2010		2009		(Decrease)		(Decrease)
Revenue from pharmaceutical products	$	63,776,505		58,438,805		5,337,700		9%
Revenue from nutraceutical products		9,934,088		9,523,090		410,998		4
Total manufacturing revenue		73,710,593		67,961,895		5,748,698		8
Distribution revenue		3,585,619		3,260,142		325,477		10
Total revenues	$	77,296,212		71,222,037		6,074,175		9%

Revenue in connection with our pharmaceutical products increased by $5,337,700, or 9%, as compared to the same period of 2009 primarily due to the following factors:

●

the sales of our prescription pharmaceutical products increased from $25,163,884 in the second quarter of 2009 to $30,396,472 in the same period of 2010, or a 21% increase. This is primarily due to the double digit increase in sales of our prescription formulated Jinji capsule, SHL powder, YYQH capsule and the expansion of CCXA generic pharmaceutical products in the rural market. The overall increase in sales was supported by our continuous marketing efforts, increase in new products offerings, as well as expanding coverage in the rural market.

●

the sales of our OTC pharmaceutical products amounted to $33,380,033, and remained stable compared to the second quarter of 2009; and

Revenue in connection with our nutraceutical products increased by $410,998, or 4%. This increase was mainly attributed to the increased sales of soybean milk as the market expanded.

The distribution revenue from Nuo Hua's majority owned subsidiary increased from $3,260,142 in the second quarter of 2009 to $3,585,619 in the same period of 2010, representing an increase of 10%. This increase was mainly attributed to Nuo Hua's expanding market coverage.

Cost of Sales and Gross Profit

Cost of sales was $37,455,860 in the second quarter of 2010, compared to $29,594,923 in the same period of 2009. Cost of sales in the second quarter of 2010 and 2009 by segments and product categories were as follows:

	Three Months Ended June 30,				Increase/		Increase/
	2010		2009		(Decrease)		(Decrease)
Pharmaceutical products	$	28,953,638		22,576,349	$	6,377,289		28%
Nutraceutical products		5,022,353		3,871,851		1,150,502		30
Total manufacturing cost		33,975,991		26,448,200		7,527,791		28
Distribution cost		3,479,869		3,146,723		333,146		11
Total cost	$	37,455,860		29,594,923	$	7,860,937		27%

The cost of sales of pharmaceutical and nutraceutical products increased by 28% and 30%, respectively, in the second quarter of 2010 compared to the same period of 2009. These increases were mainly attributed to our increase in sales and the increase in production cost. The increase in distribution costs were in line with our distribution revenue.

Gross profit decreased by $1,786,762, or 4%, for the second quarter of 2010 compared to the same period of 2009. Gross profit as a percentage of revenues decreased from 58% in the second quarter of 2009 to 52% in the same quarter of 2010 due to a greater proportion of generic product sales in the rural market. Further, the increased purchase prices of certain raw materials increased the cost of sales also contributed to lower gross profit.

Selling and Marketing Expenses

Selling and marketing expenses, including distribution expenses, increased from $9,396,129 in the second quarter of 2009 to $11,505,462 in 2010, representing a 22% increase. The details of our sales and marketing expenses were as follows:

	Three Months Ended June 30,				Increase/		Increase/
	2010		2009		(Decrease)		(Decrease)
Promotional materials and fees	$	6,980,088		6,107,927	$	872,161		14%
Payroll		2,090,093		1,338,517		751,576		56
Shipping		1,467,934		1,039,217		428,717		41
Trips and traveling		777,847		647,184		130,663		20
Office supplies		100,308		195,641		(95,333)		(49)
Miscellaneous		89,192		67,643		21,549		32
TOTAL	$	11,505,462		9,396,129	$	2,109,333		22%

The increase in selling and marketing expenses in the second quarter of 2010 compared to the same period in 2009 was primarily due to the following factors:

●

promotional materials and fees increased $872,161, or 14% in the second quarter of 2010 as compared to the same period of 2009. This was primarily due to the increase in our promotion activities and initiatives to support our continuous growth of our revenue. In particular, the Company held more external sales conference to promote existing and new prescription products such as SHL products. The increase in the promotional materials and fees is in line with the sales increase for those comparative periods;

●

payroll expense increased $751,576, or 56% in the second quarter of 2010 as compared to the same period of 2009. This was primarily due to the increase of the average salaries and bonuses for our sales people as a result of our business expanding in the rural market as well as the increase in sales volume; and

●

shipping expense increased $428,717, or 41% in the second quarter of 2010 as compared to the same period of 2009. This was primarily due to the increase in sales volume and the increase in logistics costs.

Advertising Costs

Advertising costs increased by $1,437,311, from $7,779,936 in the second quarter of 2009 to $9,217,247 in the same period of 2010. Advertising costs as a percentage of revenue increased from 11% in the second quarter of 2009 to 12% in the same period of 2010.

We increased advertising costs to create a unified mega brand for AOBO so that we can leverage on the establishment of all our individual brands to boost chances of winning in the government sponsored competitive tendering processes for China's essential drug list products as well as those on the national insurance catalogs.

We also increased advertising costs in connection with promoting our new launched products in 2009 and six months ended June 30, 2010. We believe a reasonably priced product with a brand name will be more appealing to consumers, patients and doctors.

Research and Development Costs

Research and development costs increased by $2,441,298, or 302%, from $809,584 in the second quarter of 2009 to $3,250,882 in the same period of 2010. Expressed as a percentage of revenue, research and development costs were 4% for the second quarter of 2010, compared to 1% for the same period of 2009.

The increase in research and development costs reflected our continuing effort in research and development activities. Our research and development activities consist of near term, middle team and long term stages which contribute to both our current and future business strategies. Our key research and development programs during this period include the improvement of SHL Lyophilized Injection Powder, Cease Enuresis Soft Gel, Jinji series products and some acquired projects from GHK. The majority of our research and development expenditures are on pharmaceutical products.

General and Administrative Expenses

General and administrative expenses increased by $1,131,679, or 28%, from $4,026,425 in the second quarter of 2009 to $5,158,104 in the same period of 2010. General and administrative expenses expressed as a percentage of revenues increased from 6% to 7%. The details of our general and administrative expenses were as follows:

	Three Months Ended June 30,				Increase/		Increase/
	2010		2009		(Decrease)		(Decrease)
Payroll	$	970,481		801,895	$	168,586		21%
Staff welfare and insurance		358,331		308,497		49,834		16
Professional fees		771,824		473,234		298,590		63
Directors’ remuneration		299,375		230,000		69,375		30
Stock based compensation		810,067		754,843		55,224		7
Trip and traveling		143,582		258,199		(114,617)		(44)
Maintenance and repair		132,388		21,449		110,939		517
Office supplies		298,982		171,615		127,367		74
Vehicles and utilities		193,725		120,128		73,597		61
Conference fee		67,701		101,465		(33,764)		(33)
Miscellaneous		1,111,648		785,100		326,548		42
TOTAL	$	5,158,104		4,026,425	$	1,131,679		28%

The major changes in our general and administrative expenses in the second quarter of 2010 as compared to the same period of 2009 were due to the following factors:

●

payroll expenses increased by $168,586, or 21% and Staff welfare and insurance expenses increased by $49,834, or 16% as compared to the second quarter of 2009. These reflect the Company’s increased efforts in encouraging and optimizing management team as a result of the changing market environment and China’s labor costs pressure;

●

professional fees increased by $298,590, or 63%, as compared to the second quarter of 2009. This was primarily due to the increase in accounting fees relating to the accrual of audit fees to our new independent auditor; and

●

maintenance and repair fees increased by $110,939, or 517%, as compared to the second quarter of 2009. We continued upgrading our existing equipment and technologies in the second quarter of 2010 as a result of more stringent GMP manufacturing standards as well as to improve production efficiency.

The increase was partially offset by the decrease of Trip and traveling expenses by $114,617, or 44%.

Depreciation and Amortization

Depreciation and amortization expenses remained stable in the second quarter of 2010 as compared to the same period of 2009.

Equity in Earnings (Loss) from Unconsolidated Entities

Equity in earnings (loss) from unconsolidated entities remained stable as compared to the second quarter of 2009. For additional information, see “Item 1. Financial Statements—Note 10. Investments in and advances to unconsolidated entities”

Interest Expense, Net

Net interest expense was $1,371,246 for the second quarter of 2010, compared to net interest expense of $1,620,069 for the same period of 2009. The decrease in net interest expense for the three months ended June 30, 2010 was mainly due to the increased in interest expense capitalized as Construction in progress. For additional information, see “Item 1. Financial Statements—Note 7. Construction in progress”

Income Tax

Income tax expense for the second quarter of 2010 was $2,395,850, compared to $3,735,558 for the same period of 2009. The decrease in the income tax expense was mainly due to the decline of income before income taxes. The Company’s effective tax rate for the second quarter of 2010 was 32% which is an increase of 9% from the prior year. The increase in the effective tax rate is mainly due to a decrease in profits before tax relative to permanent differences, unrecognized tax benefits and change in valuation allowance. For additional information, see “Item 1. Financial Statements—Note 17. Taxes”

RESULTS OF OPERATIONS – SIX MONTHS ENDED JUNE 30, 2010 AS COMPARED TO SIX MONTHS ENDED JUNE 30, 2009

The following table sets forth the amounts and the percentage relationship to revenues of certain items in our condensed consolidated statements of income for the six months ended June 30, 2010 and 2009:

	Six Months Ended June 30,				Six Months Ended June 30,
	2010		2009		2010		2009

Revenues	$	131,045,980		117,299,227		100%		100%
Cost of sales		62,968,907		47,255,261		48		40
GROSS PROFIT		68,077,073		70,043,966		52		60

Selling and marketing expenses		17,481,688		14,607,631		13		13
Advertising costs		15,965,717		13,347,293		12		11
Research and development costs		6,029,691		1,559,382		5		1
General and administrative expenses		9,924,590		8,417,126		8		7
Depreciation and amortization		3,219,947		3,256,142		2		3
Total operating expenses		52,621,633		41,187,574		40		35

INCOME FROM OPERATIONS		15,455,440		28,856,392		12		25
Equity in earnings (loss) from unconsolidated entities		(53,326)		264,536		0		0
Interest expense, net		2,937,031		3,199,338		2		3
Other expenses, net		17,792		114,938		0		0
INCOME BEFORE INCOME TAX		12,447,291		25,806,652		10		22
Income tax		4,211,780		6,205,322		3		5
NET INCOME		8,235,511		19,601,330		7		17
Net loss attributable to non-controlling interest		11,876		119,517		0		0
NET INCOME ATTRIBUTABLE TO CONTROLLING INTEREST	$	8,247,387		19,720,847		7		17
EARNINGS PER COMMON SHARE
Basic	$	0.11		0.27
Diluted	$	0.11		0.26

Revenues

Revenues for the six months ended June 30, 2010 were $131,045,980, an increase of $13,746,753 compared to revenues in the same period of 2009. We classify our revenues in two segments: Manufacturing revenue, which comprises sales by our subsidiaries of our pharmaceutical and nutraceutical products, and Distribution revenue. Revenues by segments and product categories were as follows:

	Six Months Ended June 30,				Increase/		Increase/
	2010		2009		(Decrease)		(Decrease)
Revenue from pharmaceutical products	$	104,641,586		93,118,274		11,523,312		12%
Revenue from nutraceutical products		19,599,791		18,435,483		1,164,308		6%
Total manufacturing revenue		124,241,377		111,553,757		12,687,620		11%
Distribution revenue		6,804,603		5,745,470		1,059,133		18%
Total revenues	$	131,045,980		117,299,227		13,746,753		12%

Revenue in connection with our pharmaceutical products increased by $11,523,312 or 12%, as compared to the same period of 2009 primarily due to the following factors:

●

the sales of our prescription pharmaceutical products increased from $41,367,074, in the six months ended June 30, 2009 to $51,342,902 in the same period of 2010, or a 24% increase. This is primarily due to the double digit increase in sales of our prescription formulated Jinji capsule, SHL powder, YYQH capsule and the expansion of CCXA generic pharmaceutical products in the rural market. The overall increase in sales was supported by our continuous marketing efforts, increase in new products offering, as well as expanding coverage in the rural market;

●

the sales of our OTC pharmaceutical products increased from $51,751,200 to $53,298,684, or a 3% increase; and

Revenue in connection with our nutraceutical products increased from $18,435,483 in the six months ended June 30, 2009 to $19,599,791 in the same period of 2010, representing an increase of 6%. This increase was mainly attributed to the increased sales of soybean milk as the market expanded.

The distribution revenue from Nuo Hua's majority owned subsidiary increased from $5,745,470 in the six months ended June 30, 2009 to $6,804,603 in the same period of 2010, representing an increase of 18%. This increase was mainly attributed to Nuo Hua's expanding market coverage.

Cost of Sales and Gross Profit

Cost of sales was $62,968,907 in the six months ended June 30, 2010, compared to $47,255,261 in the same period of 2009. Cost of sales in the same period of 2010 and 2009 by segments and product categories were as follows:

	Six Months Ended June 30,				Increase/		Increase/
	2010		2009		(Decrease)		(Decrease)
Pharmaceutical products	$	46,577,842		34,294,274	$	12,283,568		36%
Nutraceutical products		9,789,717		7,424,764		2,364,953		32%
Total manufacturing cost		56,367,559		41,719,038		14,648,521		35%
Distribution cost		6,601,348		5,536,223		1,065,125		19%
Total cost	$	62,968,907		47,255,261	$	15,713,646		33%

The cost of sales of pharmaceutical and nutraceutical products increased by 36% and 32%, respectively, in the six months ended June 30, 2010 compared to the same period of 2009. These increases were mainly attributed to our increase in sales and the increase in production cost. The increase in distribution costs were in line with the distribution revenue.

Gross profit decreased by $1,966,893, or 3% for the six months ended June 30, 2010 over the same period of 2009. Gross profit as a percentage of revenues decreased from 60% in the first half year of 2009 to 52% in the same period of 2010 due to a greater proportion of generic product sales in rural market. Further, the increased purchase prices of certain raw materials increased the cost of sales also contributed to lower gross profit.

Selling and Marketing Expenses

Selling and marketing expenses, including distribution expenses, increased from $14,607,631 in the six months ended June 30, 2009 to $17,481,688 in 2010, representing a 20% increase. The details of our sales and marketing expenses were as follows:

	Six Months Ended June 30,				Increase/		Increase/
	2010		2009		(Decrease)		(Decrease)
Promotional materials and fees	$	9,191,371		8,253,282	$	938,089		11%
Payroll		3,738,485		2,724,892		1,013,593		37
Shipping		2,441,563		1,854,302		587,261		32
Trips and traveling		1,519,197		1,266,864		252,333		20
Office supplies		240,441		310,323		(69,882)		(23)
Miscellaneous		350,631		197,968		152,663		77
TOTAL	$	17,481,688		14,607,631	$	2,874,057		20%

The increase in selling and marketing expenses in the six months ended June 30, 2010 compared to the same period in 2009 was primarily due to the following factors:

●

promotional materials and fees increased $938,089, or 11% in the six months ended June 30, 2010 as compared to the same period of 2009. This was primarily due to the increase in our promotion activities and initiatives to support our continuous growth of our revenue. In particular, the Company held more external sales conference to promote existing and new prescription products such as SHL products. The increase in the promotional materials and fees is in line with the sales increase for those comparative periods;

●

payroll expense increased $1,013,593, or 37% in the six months ended June 30, 2010 as compared to the same period of 2009. This was primarily due to the increase of the average salaries and bonuses for our sales people as a result of our business expanding in the rural market as well as the increase in sales volume; and

●

shipping expense increased $587,261, or 32% in the six months ended June 30, 2010 as compared to the same period of 2009. This was primarily due to the increase in sales volume and the increase in logistics costs.

Advertising Costs

Advertising costs increased by $2,618,424, from $13,347,293 in the six months ended June 30, 2009 to $15,965,717 in the same period of 2010. Advertising costs as a percentage of revenue increased from 11% in the six months ended June 30 2009 to 12% in the same period of 2010.

Research and Development Costs

Research and development costs increased by $4,470,309, or 287%, from $1,559,382 in the six months ended June 30 2009 to $6,029,691 in the same period of 2010. Expressed as a percentage of revenue, research and development costs were 5% for the six months ended June 30 2010, compared to 1% for the same period of 2009.

The increase in research and development costs reflected our continuing effort in research and development activities. Our research and development activities consist of near term, middle term and long term stages which contribute to both our current and future business strategies. Our key research and development programs during this period include the improvement of SHL Lyophilized Injection Powder, Cease Enuresis Soft Gel, Jinji series products and some acquired projects from GHK. The majority of our research and development expenditures are on pharmaceutical products.

General and Administrative Expenses

General and administrative expenses increased by $1,507,464, or 18%, from $8,417,126 in the six months ended June 30 2009 to $9,924,590 in the same period of 2010. General and administrative expenses expressed as a percentage of revenues increased from 7% to8%. The details of our general and administrative expenses were as follows:

	Six Months Ended June 30,				Increase/		Increase/
	2010		2009		(Decrease)		(Decrease)
Payroll	$	1,747,984		1,369,977	$	378,007		28%
Staff welfare and insurance		767,578		615,978		151,600		25
Professional fees		1,550,953		1,560,110		(9,157)		(1)
Directors’ remuneration		489,375		465,230		24,145		5
Stock based compensation		1,505,504		1,365,700		139,804		10
Trip and traveling		349,249		486,025		(136,776)		(28)
Maintenance and repair		303,306		41,894		261,412		624
Office supplies		482,041		327,152		154,889		47
Vehicles and utilities		509,881		267,625		242,256		91
Conference fee		123,905		189,084		(65,179)		(34)
Miscellaneous		2,094,814		1,728,351		366,463		21
TOTAL	$	9,924,590		8,417,126	$	1,507,464		18%

The major changes in our general and administrative expenses in the six months ended June 30, 2010 as compared to the same period of 2009 were due to the following factors:

●

payroll expenses increased by $378,007, or 28% and Staff welfare and insurance expenses increased by $151,600, or 25% as compared to the six months ended June 30 2009. These reflect the Company’s increased efforts in encouraging and optimizing management team as a result of the changing market environment and China’s labor costs pressure; and

●

maintenance and repair fees increased by $261,412, or 624%, as compared to the six months ended June 30 2009. We continued upgrading our existing equipments and technologies in the six months ended June 30 2010, as a result of more stringent GMP manufacturing standards as well as to improve production efficiency.

The increase was partially offset by the decrease of Trip and traveling expenses by $136,776, or 28%.

Depreciation and Amortization

Depreciation and amortization expenses remained stable in the six months ended June 30, 2010 as compared to the same period of 2009.

Equity in Earnings (Loss) from Unconsolidated Entities

Equity in earnings (loss) from unconsolidated entities decreased from earnings of $264,536 in the six months ended June 30, 2009 to loss of $53,326 for the same period of 2010. For additional information, see “Item 1. Financial Statements—Note 10. Investments in and advances to unconsolidated entities”

Interest Expense, Net

Net interest expense was $2,937,031 for the six months ended June 30 2010, compared to net interest expense of $3,199,338 for the same period of 2009. The decrease in net interest expense for the six months ended June 30, 2010 was mainly due to the increase in interest expense capitalized as Construction in progress. For additional information, see “Item 1. Financial Statements—Note 7. Construction in progress”

Income Tax

Income tax expense for the six months ended June 30 2010 was $4,211,780, compared to $6,205,322 for the same period of 2009. The decrease in income tax expense was mainly due to the decline of income before income taxes. The Company’s effective tax rate for the six months ended June 30 2010 was 34% which is an increase of 10% from the prior year. The increase in the effective tax rate is mainly due to a decrease in profits before tax relative to permanent differences, unrecognized tax benefits and change in valuation allowance. For additional information, see “Item 1. Financial Statements—Note 17. Taxes”

FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES

Cash

Our cash position at June 30, 2010 was $96,433,832, representing an increase of $5,307,346, or 6%, compared with our cash position of $91,126,486 at December 31, 2009. The increase was mainly attributable to the increase of operating activities of $7,739,895 and partially offset by the investing and financing activities of $1,410,240 and $1,599,192 for the six months ended June 30, 2010, respectively.

We currently generate our cash flow through operations. We expect the existing cash on hand and cash flow generated from operations will be sufficient to sustain working capital, capital expenditures, and milestone payments for the next twelve months. From time to time, we may identify new expansion opportunities for which there will be a need to use cash.

We manage our cash based on thorough consideration of our corporate strategy as well as the macro economic situation. Factors we take into account when managing our cash include interest income, foreign currency fluctuation as well as the flexibility in executing our acquisition strategy.

Working Capital

We maintain a significant level of working capital. Our working capital increased by $16,056,400 to $146,999,666 at June 30, 2010, as compared to $130,943,266 at December 31, 2009, primarily due to an increase in cash and cash equivalents by $5,307,346, an increase in net inventories by $9,000,867, and an increase in net accounts and notes receivable by $9,263,205.

Cash Flow

Our cash flows from operating, investing and financing activities, as reflected in the Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2010 and 2009, are summarized as follows:

	SIX MONTHS ENDED JUNE 30
	2010		2009
Cash provided by (used in):
Operating activities		7,739,895		26,451,742
Investing activities		(1,410,240)		4,420,524
Financing activities		(1,599,192)		(1,028,263)

Operating Activities

Cash flows from operations during the six months ended June 30, 2010 amounted to $7,739,895, representing a decrease of $18,711,847, or 71% compared with cash flows from operations of $26,451,742 in the same period of 2009. The decrease in net cash provided by operating activities was primarily attributable to the decrease in net income of $11,365,819 and changes in operating assets and liabilities aggregated to a net cash outflow of $9,025,102 and a decrease by $7,366,561 from a net cash outflow of $1,658,541 during the same period of 2009. As reflected in our cash flows, the changes included:

●

Cash outflow from accounts and notes receivable amounted to $9,346,105 primarily affected by the increase of our sales revenue during the six month ended June 30, 2010;

●

Cash outflows from inventories amounted to $8,997,546 mainly due to the increased purchases of raw materials and finished goods for planned inventory build-up for the coming peak sales season;

●

Cash inflow from advances to suppliers and prepaid expenses amounted to $7,995,584 primarily attributed to the decrease in advances payments in purchasing certain raw materials at the year end of 2009. These advance payments were for a potential increase of raw materials’ future purchase prices and most of them were settled with inventories by our suppliers during the second quarter ended June 30, 2010;

●

Cash inflows from accounts payable amounted to $3,849,965 primarily attributed to the increased purchases of raw materials for planned inventory build-up; and

●

Cash outflows from other payables and accrued expenses amounted to $5,831,985 primarily attributed to the decreased VAT payable balance for the slack sales season of first half year of 2010 and the payment of sales commissions accrued at December 31, 2009.

Investing Activities

Our net cash used in investing activities amounted to $1,410,240 during the six months ended June 30, 2010, compared to net cash provided by investing activities of $4,420,524 in the same period of 2009. The Changes in net cash used in investing activities were primarily attributable to the return of a refundable deposit of $6,396,996 in the same period of 2009 for due diligence.

Financing Activities

Our cash flows used in financing activities amounted to $1,599,192 during the six months ended June 30, 2010, compared to cash outflow of $1,028,263 in the same period of 2009. The increase in net cash used in financing activities was mainly attributable to the increase of net repayment of bank loans.

Off -balance Sheet Arrangements

We do not have any off -balance sheet arrangements as of June 30, 2010.

Contractual Obligations

The following table summarizes the Company's estimated contractual obligations as of June 30, 2010:

	Payments due by period
	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
Purchase obligations		1,770,359		1,770,359		-		-		-
Capital expenditure commitments		20,027,226		11,411,652		8,615,574		-		-
Advertising commitments		17,961,196		17,961,196		-		-		-
R&D commitments		5,052,206		4,170,968		881,238		-		-
Long-term loan		771,227		60,629		125,895		132,345		452,358
Convertible Notes		143,989,583		5,750,000		11,500,000		11,500,000		115,239,583
Total		189,571,797		41,124,804		21,122,707		11,632,345		115,691,941

Holders of the convertible notes may require the Company to repurchase all or a portion of their notes on July 15, 2013 for cash at a price equal to 100% of the principal amount of the notes to be purchased, plus accrued and unpaid interest, if any, up to, but excluding, the repurchase date.

We rely largely on operating cash flow to fund our capital expenditure needs. Due to our significant operating cash flow, we believe we have the ability to meet our capital expenditure needs and foresee no delays to planned capital expenditures.

ISSUANCE OF COMMON STOCK

The following summarizes the issuance of our equity securities during the three month ended June 30, 2010:

During the three months ended June 30, 2010, the Company issued 80,375 shares of restricted common stock to five of its independent directors. The shares issued were part of the total compensation for their services rendered in 2009.

During the three months ended June 30, 2010, the Company issued 103,328 shares of restricted common stock to employees based on a graded vesting schedule of 20% per fully completed year (based on each subsequent one-year anniversary of the date of grant).

During the three months ended June 30, 2010, the Company issued 74 , 996 shares of common stock to consultants for advisory services rendered and to be rendered in 2010.

INFLATION

Inflation has not had a material impact on our business.

CURRENCY EXCHANGE FLUCTUATIONS

The Company's operations are exposed to a variety of global market risks, including the effect of changes in foreign currency exchange rates. These exposures are managed, in part, with the use of a financial derivative. The Company does not use financial derivatives to hedge exposures in the ordinary course of business or for speculative purposes.

We currently conduct substantially all of our operations through our PRC subsidiaries. The functional currency of our PRC subsidiaries is the Chinese RMB. The financial statements of our PRC subsidiaries are translated to U.S. dollars using year-end exchange rates as to assets and liabilities and average exchange rates as to revenues, expenses, and cash flows. Capital accounts are translated at their historical exchange rates when the capital transaction occurred. Translation adjustments resulting from this process are included in accumulated other comprehensive income in the statement of shareholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred.

As the majority of our net revenue, consolidated costs and expenses and substantially all of our assets are denominated in RMB, any significant revaluation of the RMB may materially and adversely affect our cash flows, revenues and financial condition. For example, if the RMB depreciates against the U.S. dollar, the value of our RMB revenues, earnings, and assets, as expressed in our U.S. dollar financial statements could decline. In addition, if we decide to convert our RMB into U.S. dollars for the purpose of making payments for business purposes, the U.S. dollar equivalent of the RMB we convert would be reduced. On the other hand, to the extent that we need to convert U.S. dollars we receive from an offering of our securities into RMB for our operations, appreciation of the RMB against the U.S. dollar could reduce the amount of the U.S. dollars available. In addition, the appreciation of the RMB could make our customers’ products more expensive to purchase, because some of our customers are involved in the export of goods, which may have an adverse impact on their sales. A decrease in sales by our customers could have an adverse effect on our operating results.

The local currencies in the countries in which we sell our products may fluctuate in value in relation to other currencies. Such fluctuations may affect the costs of our products sold and the value of our local currency profits. While we are not conducting any operations in countries other than China at the present time, we may expand to other countries and may then have an increased risk of exposure of our business to currency fluctuation.

The PRC government imposes control over the conversion of RMB, into foreign currencies. Under the current unified floating exchange rate system, the People’s Bank of China publishes an exchange rate, which we refer to as the PBOC exchange rate, based on the previous day’s dealings in the inter-bank foreign exchange market. Financial institutions authorized to deal in foreign currency may enter into foreign exchange transactions at exchange rates within an authorized range above or below the PBOC exchange rate according to market conditions.

Pursuant to the Foreign Exchange Control Regulations of the PRC issued by the State Council which came into effect on April 1, 1996, and the Regulations on the Administration of Foreign Exchange Settlement, Sale and Payment of the PRC which came into effect on July 1, 1996, regarding foreign exchange control, conversion of RMB into foreign exchange by Foreign Investment Enterprises, or FIEs, for use on current account items, including the distribution of dividends and profits to foreign investors, is permissible. FIEs are permitted to convert their after-tax dividends and profits to foreign exchange and remit such foreign exchange to their foreign exchange bank accounts in China. Conversion of RMB into foreign currencies for capital account items, including direct investment, loans, and security investment, is still under certain restrictions. On January 14, 1997, the State Council amended the Foreign Exchange Control Regulations and added, among other things, an important provision, which provides that the PRC government shall not impose restrictions on recurring international payments and transfers under current account items.

Enterprises in China, including FIEs, which require foreign exchange for transactions relating to current account items, if within a certain limited amount may, without approval of the State Administration of Foreign Exchange, or SAFE, effect payment from their foreign exchange account or convert and pay at the designated foreign exchange banks by providing valid receipts and proofs.

Convertibility of foreign exchange in respect of capital account items, such as direct investment and capital contribution, is still subject to certain restrictions, and prior approval from the SAFE or its relevant branches must be sought.

Between 1994 and 2004, the exchange rate for RMB against the U.S. dollar remained relatively stable, most of the time in the region of approximately RMB8.28 to US$1.00. However, in 2005, the Chinese government announced that it would begin pegging the exchange rate of the RMB against a number of currencies, rather than just the U.S. dollar.

Since a significant amount of our future revenues are expected to be denominated in RMB, any existing and future restrictions on currency exchange may limit our ability to utilize revenue generated in China to fund our business activities outside of China, if any, or expenditures denominated in foreign currencies, or our ability to meet our foreign currency obligations, which could have a material adverse effect on our business, financial condition and results of operations. We cannot be certain that the PRC regulatory authorities will not impose more stringent restrictions on the convertibility of RMB with respect to foreign exchange transactions.

We recognized a foreign currency translation adjustment of $1,936,503 and $513,282 for the six months ended June 30, 2010 and 2009, respectively. The balance sheet amounts with the exception of equity at June 30, 2010 were translated at 6.8086 RMB to $1.00 USD as compared to 6.8372 RMB at December 31, 2009. The equity accounts were stated at their historical rate. The average translation rates applied to the income and cash flow statement amounts for the six months ended June 30, 2010 and 2009 were 6.8229 RMB and 6.8495 RMB to $1.00 USD, respectively. We do not hedge our exposure to foreign exchange risk; as such, we may in the future experience economic loss as a result of any foreign currency exchange rate fluctuations.

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There were no material changes in the Company’s market risk components since December 31, 2009. For a discussion of our market risk, see “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our 2009 Annual Report on Form 10-K.

ITEM 4 – CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report (the “Evaluation Date”), we carried out an evaluation in accordance with the requirements of auditing standards and applicable U.S. rules. The Company’s internal audit group, which includes its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with respect to this Quarterly Report on Form 10-Q before its filing with the Commission. The internal audit group made its evaluation pursuant to Rule 13a-15 under the Exchange Act.

Based upon our evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that, as of the Evaluation Date, the Company's disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the second quarter of 2010 covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1 – LEGAL PROCEEDINGS

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of our executive officers or any of our subsidiaries, threatened against or affecting our company, our common stock, or any of our subsidiaries, or against our Company’s or our Company’s subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

ITEM 1A – RISK FACTORS

There have been no material changes or new risks since our Annual Report on Form 10-K for the year ended December 31, 2009.

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended June 30, 2010, the Company issued 74,996 shares of common stock to consultants for advisory services rendered and to be rendered in 2010.

The issuance of the foregoing shares was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

There have been no material defaults.

ITEM 4 – OTHER INFORMATION

Not applicable.

ITEM 5 – EXHIBITS

The following exhibits are filed as part of this Quarterly Report on Form 10-Q:

Exhibit No.	Description
31.1	Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a – 14(a) of the Securities Exchange Act, as amended
31.2	Certification of Acting Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a – 14(a) of the Securities Exchange Act, as amended
32.1	Certification of Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. 1350, as adopted.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMERICAN ORIENTAL BIOENGINEERING, INC.

/s/ Tony Liu

TONY LIU

CHAIRMAN AND CHIEF EXECUTIVE OFFICER

DATED: August 9, 2010

/s/ Yanchun Li

YANCHUN LI

CHIEF FINANCIAL OFFICER

DATED: August 9, 2010

EXHIBIT INDEX

Exhibit No.	Description
31.1	Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a – 14(a) of the Securities Exchange Act, as amended
31.2	Certification of Acting Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a – 14(a) of the Securities Exchange Act, as amended
32.1	Certification of Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. 1350, as adopted.

American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more American Oriental Bioengineering, Inc. Charts.

American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jul 2023 to Jul 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AOB American Oriental Bioengineering, Inc.

News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AOB American Oriental Bioengineering, Inc.

News

Your Recent History

Company

Business

Popular

Get The App